Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Autologous tumor therapy]

S P Hauser

    Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis
    |September 28, 1993
    PubMed
    Summary
    This summary is machine-generated.

    Autologous Target Cytokine (ATC) therapy, a novel cancer treatment, lacks scientific validation and clinical evidence. Despite claims of efficacy for all cancers, its unproven mechanisms and undisclosed production raise significant concerns among oncologists.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Transient thrombopoietin peak after liver transplantation for end-stage liver disease.

    British journal of haematology·2001
    Same author

    Autosomal dominant inheritance of scapuloiliac dysostosis.

    American journal of medical genetics·2001
    Same author

    Quality assurance in thrombapheresis.

    Transfusion science·2000
    Same author

    Effects of unprocessed and processed cardiopulmonary bypass blood retransfused into patients after cardiac surgery.

    The International journal of artificial organs·1999
    Same author

    Effects of myelotoxic agents on cytokine production in murine long-term bone marrow cultures.

    Stem cells (Dayton, Ohio)·1998
    Same author

    Long-term treatment of chronic relapsing inflammatory demyelinating polyradiculoneuropathy: combination of corticosteroids, plasma exchange, and intravenous immunoglobulins.

    European neurology·1998

    Area of Science:

    • Oncology
    • Immunotherapy
    • Cellular Therapy

    Context:

    • A Munich-based dermatologist proposed three therapies: transoptin, tumor identification training for autologous immunocompetent cells (TI-TAI), and autologous target cytokine (ATC) therapy.
    • ATC therapy is presented as a universal treatment for cancers and immunodeficiencies, with purported positive effects.

    Purpose:

    • To critically evaluate the scientific basis and clinical evidence for the proposed ATC therapy.
    • To highlight the unconventional terminology, unproven in-vitro lymphocyte training, and undisclosed production methods associated with the therapy.

    Summary:

    • The ATC therapy involves culturing patient's tumor cells and leukocytes, stimulating tumor cell division, and training autologous immunocompetent cells to identify and target tumor cells.
    • Cytokines produced by lymphocytes are harvested and administered subcutaneously. Each cycle costs approximately 3000 DM.

    Related Experiment Videos

  • The dermatologist's methodology employs unconventional terms, and the in-vitro lymphocyte training for tumor defense remains experimentally unproven. The mechanisms of action and clinical efficacy are unclear.

    • Impact:

    • The lack of scientific rigor and transparency surrounding ATC therapy raises concerns about its safety and efficacy.
    • Oncologists have reported adverse effects such as fatigue, fever, pain, lymphopenia, and leukocytosis, contradicting the denial of side effects.
    • Further research and transparent reporting of data are crucial to validate or refute the claims made about ATC therapy.